BROWSE IAS 2009 COVERAGE
|
 | |
 |
African Americans, Women Have Lower Virologic Response Rates in Both Arms of Head-to-Head Antiretroviral Trial
Race and gender may prove to be a more critical factor than we think in virologic response to HIV medications. In the large HEAT study, which compared two first-line HAART regimens, Kimberly Smith, M.D., M.P.H., et al found that in both study arms, fewer African Americans (versus white patients) and females (versus males) achieved a viral load of less than 50 copies/mL. (From The Body PRO)
|
IAS 2009 itself has officially ended, but our coverage has just begun!
|
|
More Top Stories:
- The Latest HIV/AIDS Treatment and Prevention Research From IAS 2009: A Discussion With Activists Bob Munk and Matt Sharp
(From The Body)
- Antiretroviral Therapy Highlights From IAS 2009
Tune in as Joel Gallant, M.D., M.P.H., one of the United States' foremost HIV experts, walks us through some of the most important findings in HIV treatment strategies presented at the conference. (From The Body PRO)
- HIV's Silent Dangers Make Early HIV Treatment Critical, Expert Says
"During the long period when the person appears to be quite well, there are ongoing processes in their bodies, due to HIV itself ... that may be causing some damage, some unseen damage, that may ultimately have a very large impact on a person's survival, and a person's wellness," says Wafaa El-Sadr, M.D., M.P.H. El-Sadr, one of the world's most respected HIV researchers, made this key point at the IAS 2009 conference in the midst of an eloquent call for early HIV treatment and global access to HIV meds. (From The Body PRO)
- Study Examines Efficacy of Isentress (Raltegravir)
Isentress failed to "reduce low-level reservoirs of HIV," in a 53-participant study of HIV-positive patients whose viral loads were already at undetectable levels. (From kaisernetwork.org)
- Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests
Patients taking nevirapine may have a lower risk of developing cardiovascular disease than those taking ritonavir-boosted atazanavir, according to a 569-patient study by European researchers. The study found that although nevirapine's efficacy was non-inferior to that of atazanavir, nevirapine appeared to have a more favorable lipid profile. (From kaisernetwork.org)
- Experimental Integrase Inhibitor GSK-572 Looks Good in Early Studies
A second-generation integrase inhibitor -- S/GSK1349572, or GSK-572 for short -- demonstrated very good antiviral activity in a 10-day monotherapy study, researchers reported. (From aidsmap.com)
- Once-Daily Kaletra Found as Safe and Effective as Twice-Daily Dosing in Treatment-Experienced Patients
Lopinavir/ritonavir taken once-daily as part of a combination antiretroviral regimen worked as well as the approved twice-daily dose in previously treated patients -- but also led to better adherence, researchers reported. (From aidsmap.com)
- Small Clinical Trial Examines Drug's Ability to Reduce HIV in Body
In the first human trial of the experimental integrase inhibitor S/GSK1349572, the drug was able to reduce HIV to undetectable levels in 70 percent of the 35 patients taking the treatment for 10 days. (From kaisernetwork.org)
- Boosted Darunavir Monotherapy Works Well in Two Studies
Ritonavir-boosted darunavir alone maintains HIV suppression in most patients who achieved an undetectable viral load on combination antiretroviral therapy, according to two studies. (From aidsmap.com)
- Boosted and Unboosted Atazanavir Maintain Viral Suppression Equally Well
Unboosted atazanavir taken once-daily as part of a combination antiretroviral regimen can keep viral load undetectable in patients who discontinue ritonavir, researchers reported. (From aidsmap.com)
- Acyclovir Reduces Disease Progression and Death in People With HIV by Nearly 20% -- But Doesn't Reduce Transmission Risk
HIV-infected people given 400 mg of acyclovir twice-daily as part of a trial to see if the drug reduced HIV transmission in serodiscordant couples were 17% less likely to progress to AIDS, have to start antiretroviral therapy, or die. (From aidsmap.com)
- Raltegravir Moves Closer to Approval for First-Line Use in Europe
A European regulatory committee has recommended expanding raltegravir's marketing authorization to include individuals initiating HAART. The recommendation comes days after trial data was presented about the safety and efficacy of the drug in treatment-naive patients. (From aidsmap.com)
- Nevirapine Matches Atazanavir/Ritonavir in 48-Week Study
Nevirapine has equivalent efficacy to atazanavir/ritonavir when combined with tenofovir and emtricitabine in treatment-naive patients, results from the ARTEN study show. (From aidsmap.com)
- Genotypic Test Matches Tropism Test in Predicting Who Benefits From CCR5 Inhibitors
A genotypic test is just as accurate as a more expensive tropism test in determining which treatment-experienced patients are suitable for treatment with the CCR5 inhibitor maraviroc, researchers from the University of British Columbia reported. (From aidsmap.com)
- Everything Antiretroviral: 5th IAS Conference, Cape Town, South Africa
A series of brief, down-to-earth summaries of studies on: the "when to start" question; pre-exposure prophylaxis; complications of HAART; aging and HIV; and the latest developments in the search for a cure. (From Project Inform)
- Can the Establishment and Persistence of HIV Reservoirs Ever Be Controlled?
Study summary by Françoise Barré-Sinoussi, Ph.D. (From The Body PRO)
- More Coming Soon!
|
|
Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
|
|
|
Email
Glossary
